Literature DB >> 29769853

Summary of recommendations for the prevention of viral hepatitis during travel.

.   

Abstract

Viral hepatitis is considered the most common travel-related, vaccine-preventable disease. All non-immune travellers to developing countries should consider vaccination with inactivated Hepatitis A (HA) virus vaccine and recombinant Hepatitis B (HB) virus vaccine. Inactivated HA and recombinant HB vaccines are safe, have few side effects and are effective in providing long-lasting protection. All monovalent HA and HB vaccines available for use within Canada are equally effective, and each can be used interchangeably. HA Ig (immune globulin) should be used to prevent HA only in those for whom active HA vaccines are contraindicated, in immunocompromised individuals who may not respond adequately to the active vaccines or in infants less than one year of age. All travellers should practise routine protective measures when abroad. HB virus carriers travelling to Hepatitis D virus-endemic countries should be particularly vigilant in avoiding high-risk activities such as skin piercing and unsafe sexual practices.

Entities:  

Year:  2014        PMID: 29769853      PMCID: PMC5864484          DOI: 10.14745/ccdr.v40i13a03

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  17 in total

1.  An Advisory Committee Statement (ACS). Statement on travellers' diarrhea.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2001-03-15

Review 2.  Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates.

Authors:  Yvan J F Hutin; Anja M Hauri; Gregory L Armstrong
Journal:  BMJ       Date:  2003-11-08

3.  Statement on hepatitis vaccines for travellers. An Advisory Committee Statement (ACS).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2008-07

4.  Seroprevalence of hepatitis C in a Canadian federal penitentiary for women.

Authors:  P M Ford; C White; H Kaufmann; J MacTavish; M Pearson; S Ford; P S Mistry; P Connop
Journal:  Can Commun Dis Rep       Date:  1995-07-30

5.  Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial.

Authors:  L Sagliocca; P Amoroso; T Stroffolini; B Adamo; M E Tosti; G Lettieri; C Esposito; S Buonocore; P Pierri; A Mele
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

Review 6.  Hepatitis A vaccine in the last-minute traveler.

Authors:  Bradley A Connor
Journal:  Am J Med       Date:  2005-10       Impact factor: 4.965

Review 7.  Hepatitis A vaccine: ready for prime time.

Authors:  B Duff; P Duff
Journal:  Obstet Gynecol       Date:  1998-03       Impact factor: 7.661

8.  Hepatitis A virus infections in travelers, 1988-2004.

Authors:  Margot Mutsch; Virginie Masserey Spicher; Christoph Gut; Robert Steffen
Journal:  Clin Infect Dis       Date:  2006-01-11       Impact factor: 9.079

9.  Risks of hepatitis B in travelers as compared to immunization status.

Authors:  J N Zuckerman; R Steffen
Journal:  J Travel Med       Date:  2000 Jul-Aug       Impact factor: 8.490

10.  Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.

Authors:  J N Zuckerman; C T Kirkpatrick; M Huang
Journal:  J Travel Med       Date:  1998-03       Impact factor: 8.490

View more
  2 in total

Review 1.  Travel vaccines: Update for Canadian pharmacists.

Authors:  Christina Bascom
Journal:  Can Pharm J (Ott)       Date:  2019-10-11

2.  Summary of the Statement on International Travellers Who Intend to Visit Friends and Relatives.

Authors:  J Brophy
Journal:  Can Commun Dis Rep       Date:  2015-05-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.